Finance

Beta
Lists
ACRV:NASDAQ
Acrivon Therapeutics Inc
$1.80
+1.16%
(+0.021) 1D
Jul 1, 10:04:13 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRV...
Open
$1.77
High
$1.80
Low
$1.75
Mkt. cap
76.83M
Avg. vol.
392.60K
Volume
48.74K
52-wk high
$3.56
52-wk low
$1.15
EPS
-$2.00
Beta
1.89
Shares outstanding
42.80M
No. of employees
75
Open
$1.77
High
$1.80
Low
$1.75
Mkt. cap
76.83M
Avg. vol.
392.60K
Volume
48.74K
52-wk high
$3.56
52-wk low
$1.15
EPS
-$2.00
Beta
1.89
Shares outstanding
42.80M
No. of employees
75
News stories
From sources across the web
About Acrivon Therapeutics Inc
CEO-
Employees75
Founded2018
HeadquartersWatertown, Massachusetts, United States
SectorBiotechnology
Websiteacrivon.com
Analyst ratings
Based on 5 analysts giving stock ratings to ACRV in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ACRV in the last 3 months.
Highest
Current $1.80
$19.00 (+955.15%)
Average
$10.50 (+483.11%)
Lowest
$7.00 (+288.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeff Jonas
Gabelli
Buy
Initiated
$8.00
+344.3%
06/15/2026
Jeff Jones
Oppenheimer
Buy
Initiated
$8.00
+344.3%
06/15/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
$7.00
+288.7%
05/18/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
05/14/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$8.00
+344.3%
05/14/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$19.00
+955.1%
05/14/2026
Unknown Analyst
Jefferies
Buy
Maintained
$14.00
+677.5%
03/20/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$8.00
+344.3%
03/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
16.18M
13.65M
14.75M
15.17M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.47M
6.04M
5.37M
4.74M
Operating expense
22.65M
19.69M
20.12M
19.90M
Total operating expenses
22.65M
19.69M
20.12M
19.90M
Operating income
-22.65M
-19.69M
-20.12M
-19.90M
Other non operating income
-87.00K
-53.00K
-753.00K
-129.00K
EBT including unusual items
-21.01M
-18.23M
-18.98M
-19.04M
EBT excluding unusual items
-21.01M
-18.23M
-19.42M
-19.04M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21.01M
-18.23M
-18.98M
-19.04M
Net profit margin
-
-
-
-
Earnings per share
-0.55
-0.47
-0.49
-0.49
Interest and investment income
1.73M
1.51M
1.25M
989.00K
Interest expense
-
-
-
-
Net interest expenses
1.73M
1.51M
1.25M
989.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.31M
-19.34M
-19.76M
-19.52M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer